Recently, MDX-1106, a humanized IgG4 anti-PD-1 monoclonal antibody, as another type of the PD-1 inhibitors exhibited antitumor activity in metastatic melanoma, CRC, castrate-resistant prostate cancer (CRPC), NSCLC and RCC patients [145]. This evidence concerns the gene PDCD1 and renal cell carcinoma.